Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

341. Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD

Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Article Text Therapeutics Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2008

342. Outcomes for COPD pharmacological trials: from lung function to Biomarkers

Outcomes for COPD pharmacological trials: from lung function to Biomarkers Options

European Respiratory Society2008

343. Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve breathlessness in COPD

Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve breathlessness in COPD Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve breathlessness in COPD | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve breathlessness in COPD Article Text Treatment Review: walking aids, chest-wall vibration, and neuroelectrical muscle stimulation relieve

Evidence-Based Nursing (Requires free registration)2008

344. Review: corticosteroids plus long-acting Beta-agonists reduce exacerbations more than long-acting Beta-agonists alone in COPD

Review: corticosteroids plus long-acting Beta-agonists reduce exacerbations more than long-acting Beta-agonists alone in COPD Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone in COPD Article Text Therapeutics Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone

Evidence-Based Medicine (Requires free registration)2008

345. Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD

Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD Article Text Therapeutics Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish

Evidence-Based Medicine (Requires free registration)2008

346. Implications of prognostic pessimism in patients with chronic obstructive pulmonary disease (COPD) or asthma admitted to intensive care in the UK within the COPD and asthma outcome study (CAOS): multicentre observational cohort study.

Implications of prognostic pessimism in patients with chronic obstructive pulmonary disease (COPD) or asthma admitted to intensive care in the UK within the COPD and asthma outcome study (CAOS): multicentre observational cohort study. OBJECTIVE: To determine whether clinicians' prognoses in patients with severe acute exacerbations of obstructive lung disease admitted to intensive care match observed outcomes in terms of survival. DESIGN: Prospective cohort study. SETTING: 92 intensive (...) care units and three respiratory high dependency units in the United Kingdom. PARTICIPANTS: 832 patients aged 45 years and older with breathlessness, respiratory failure, or change in mental status because of an exacerbation of COPD, asthma, or a combination of the two. MAIN OUTCOME MEASURES: Outcome predicted by clinicians. Observed survival at 180 days. RESULTS: 517 patients (62%) survived to 180 days. Clinicians' prognoses were pessimistic, with a mean predicted survival of 49% at 180 days

BMJ2007 Full Text: Link to full Text with Trip Pro

347. Formoterol (Easyhaler) - relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary diesease (COPD)

Formoterol (Easyhaler) - relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary diesease (COPD) Scottish Medicines Consortium formoterol 12 micrograms metered dose inhaler (Atimos® Modulite ® ) No. (349/07) Trinity-Chiesi Ltd Product Update 9 February 2007 (Issued October 2007) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees on its use in NHS Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission formoterol 12 micrograms metered dose inhaler (Atimos® Modulite ® ) is accepted for use in NHS Scotland for the relief of broncho-obstructive symptoms in patients with chronic obstructive pulmonary disease (COPD). It should be used in patients for whom formoterol is an appropriate choice of long-acting beta-agonist and for whom a metered dose inhaler is an appropriate delivery device. Advice context: No part of this advice

Scottish Medicines Consortium2007

348. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study.

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a growing cause of morbidity and mortality worldwide, and accurate estimates of the prevalence of this disease are needed to anticipate the future burden of COPD, target key risk factors, and plan for providing COPD-related health services. We aimed to measure the prevalence of COPD and its risk factors and investigate variation (...) across countries by age, sex, and smoking status. METHODS: Participants from 12 sites (n=9425) completed postbronchodilator spirometry testing plus questionnaires about respiratory symptoms, health status, and exposure to COPD risk factors. COPD prevalence estimates based on the Global Initiative for Chronic Obstructive Lung Disease staging criteria were adjusted for the target population. Logistic regression was used to estimate adjusted odds ratios (ORs) for COPD associated with 10-year age

Lancet2007

349. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study.

Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in China, where the population is also exposed to high levels of passive smoking, yet little information exists on the effects of such exposure on COPD. We examined the relation between passive smoking and COPD and respiratory symptoms in an adult Chinese population. METHODS: We used baseline data from (...) the Guangzhou Biobank Cohort Study. Of 20 430 men and women over the age of 50 recruited in 2003-06, 15,379 never smokers (6497 with valid spirometry) were included in this cross-sectional analysis. We measured passive smoking exposure at home and work by two self-reported measures (density and duration of exposure). Diagnosis of COPD was based on spirometry and defined according to the GOLD guidelines. FINDINGS: There was an association between risk of COPD and self-reported exposure to passive smoking at

Lancet2007

350. Global burden of COPD: risk factors, prevalence, and future trends.

Global burden of COPD: risk factors, prevalence, and future trends. Chronic obstructive pulmonary disease (COPD) continues to be an important cause of morbidity, mortality, and health-care costs worldwide. It is a global health issue, with cigarette smoking being an important risk factor universally; other factors, such as exposure to indoor and outdoor air pollution, occupational hazards, and infections, are also important. As the global population ages, the burden of COPD will increase in (...) years to come. Prevalence estimates of the disorder show considerable variability across populations, suggesting that risk factors can affect populations differently. Other advances in our understanding of COPD are increased recognition of the importance of comorbid disease, identification of different COPD phenotypes, and understanding how factors other than lung function affect outcome in our patients. The challenge we will all face in the next few years will be implementation of cost-effective

Lancet2007

351. What have we learned from large drug treatment trials in COPD?

What have we learned from large drug treatment trials in COPD? Although the development of effective treatments for patients with chronic obstructive pulmonary disease (COPD) has not been seen as a high priority, the past decade has seen a substantial increase in the number of clinical studies examining different treatments for this disease. Large studies are needed to adequately assess the effectiveness of treatment because of the chronic nature of the disease and the intermittent occurrence (...) , but results of these studies can be affected by differences in inclusion criteria and patient dropout during the study. Bronchodilator reversibility testing does not reliably define subgroups that will respond to a particular treatment. Carefully done and adequately powered clinical trials continue to inform, not only our views about treatment, but also our understanding of COPD and how it is best assessed and managed. Ensuring that these expensive studies are done objectively to the highest standard

Lancet2007

352. COPD exacerbations: defining their cause and prevention.

COPD exacerbations: defining their cause and prevention. Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, leading to substantial morbidity and mortality. COPD exacerbations are associated with increased airway and systemic inflammation and physiological changes, especially the development of hyperinflation. They are triggered mainly by respiratory viruses and bacteria, which infect the lower airway and increase airway inflammation. Some (...) patients are particularly susceptible to exacerbations, and show worse health status and faster disease progression than those who have infrequent exacerbations. Several pharmacological interventions are effective for the reduction of exacerbation frequency and severity in COPD such as inhaled steroids, long-acting bronchodilators, and their combinations. Non-pharmacological therapies such as pulmonary rehabilitation, self-management, and home ventilatory support are becoming increasingly important

Lancet2007

353. Review: cardioselective ß blockers do not produce adverse respiratory effects in COPD

Review: cardioselective ß blockers do not produce adverse respiratory effects in COPD Review: cardioselective β blockers do not produce adverse respiratory effects in COPD | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main (...) menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: cardioselective β blockers do not produce adverse respiratory effects in COPD Article Text Therapeutics Review: cardioselective β blockers do not produce adverse respiratory effects in COPD Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all

Evidence-Based Medicine (Requires free registration)2007

354. A 68-year-old man with COPD contemplating colon cancer surgery.

A 68-year-old man with COPD contemplating colon cancer surgery. Mr A is a 68-year-old man with a history of melena who was found to have a mass in his colon that was suspicious for possible malignancy. His 75-pack-year smoking history has resulted in a chronic daily cough and the diagnosis of chronic obstructive pulmonary disease. On physical examination, he has wheezes, decreased breath sounds, and a prolonged expiratory phase; his forced expiratory volume in the first second (FEV1) is 1.34 L

JAMA2007

356. Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients

Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients Dal Negro R, Eandi M, Pradelli L, Iannazzo S Record Status (...) with chronic obstructive pulmonary disease (COPD), in agreement with the Global Initiative for Chronic Lung Disease (GOLD) recommendations. These included: combined salmeterol/fluticasone (SF), 50/500 μg twice daily (b.i.d.) in GOLD Stages III and IV patients in addition to the standard therapy already in use; combined formoterol/budesonide (FB), 160/4.5 μg b.i.d. in GOLD Stages III and IV patients in addition to the standard therapy already in use. The comparators were: fluticasone, 500 μg b.i.d. in GOLD Stages III and IV patients

NHS Economic Evaluation Database.2007

357. Systematic review of noninvasive positive pressure ventilation in severe stable COPD

Systematic review of noninvasive positive pressure ventilation in severe stable COPD Systematic review of noninvasive positive pressure ventilation in severe stable COPD Systematic review of noninvasive positive pressure ventilation in severe stable COPD Kolodziej M A, Jensen L, Rowe B, Sin D CRD summary The authors concluded that bi-level non-invasive positive pressure ventilation may be a useful adjunct for a subset of patients with severe stable chronic obstructive pulmonary disease (...) . Findings appeared to support the conclusions, but the assessment of multiple outcomes from generally small short-term studies meant that the evidence was limited and caution is advised. Authors' objectives To evaluate the effectiveness of bi-level non-invasive positive pressure ventilation (NIPPV) in patients with chronic respiratory failure (CRF) due to severe stable chronic obstructive pulmonary disease (COPD). Searching MEDLINE/Pre-MEDLINE/PubMed, EMBASE, CINAHL, Conference Papers Index, Online

DARE.2007

358. Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life

Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Article Text Therapeutics Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Free Matthew B Stanbrook , MD, PhD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2006

359. Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness

Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness Article Text Qualitative Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness Free Paula M Meek , PhD , RN

Evidence-Based Nursing (Requires free registration)2006

360. Administration of steroids in acute exacebations of COPD

Administration of steroids in acute exacebations of COPD BestBets: Administration of steroids in acute exacerbations of COPD Administration of steroids in acute exacerbations of COPD Report By: Shweta Gidwani - Clinical Effectiveness Fellow in Emergency Medicine Search checked by Craig Ferguson - Clinical Research Fellow Institution: Manchester Royal Infirmary Date Submitted: 8th June 2005 Date Completed: 8th February 2006 Last Modified: 8th June 2005 Status: Green (complete) Three Part (...) Question In [patients with an acute exacerbation of COPD] are [steroids prior to discharge better than no steroids] at [improving outcome and hastening recovery]? Clinical Scenario A 55yr old man, known to have COPD comes to casulty more short of breath than usual and with a history of recently coughing purulent sputum. You treat him in the ED with continuous nebulised bronchodilater therapy, oral steroids as well as antibiotics. He starts to improve and on reasessing him clinically, after reviewing

BestBETS2006